Amyris Announces Closings of Conversion and Restructuring of Approximately $175 Million of Convertible Debt and $25 Million Private Placement

EMERYVILLE, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Amyris, Inc. AMRS, the industrial bioscience company, today announced the closings of both its previously announced transactions for the conversion and restructuring of approximately $175 million of outstanding convertible debt into Amyris common stock, and a private placement of its common stock for aggregate proceeds of approximately $25 million. The company noted that details of these transactions are included in a related Form 8-K, which the company filed today in conjunction with this news release with the Securities and Exchange Commission (SEC).

About Amyris

Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.

Amyris and the Amyris logo are registered trademarks of Amyris, Inc.

Note to Editors: Please see news release issued June 27, 2015, entitled, "Amyris Announces Signing of Agreements for Conversion and Restructuring of Approximately $175 Million of Convertible Debt and $25 Million Private Placement."